Canterbury DHB


Influenza and Respiratory Illnesses

See Infection Prevention and Control: Influenza and Viral Respiratory Illness Guidelines.

Patients who are thought clinically to be at risk of having influenza and other respiratory viral illnesses must not be on the Bone Marrow Transplant unit as these can result in a high mortality in allogeneic transplant patients. Studies show the mortality for community respiratory viruses to be between 30-40%, and higher in adenovirus and influenza A. (Respiratory Tract Infections In Bone Marrow Transplant Patients, Transplantation, 2003:76:142-6. Raboni, Sonia.)

In view of the risk of influenza in immunosuppressed patients, oseltamivir prophylaxis should be given to individuals who have shared a room in the previous 48 hours. The prophylactic dose is 75 mg ONCE daily for 10 days.

Patients with clinical influenza syndrome should not be admitted to the B6 unless there is a clear indication to do so. If they need to be admitted to the B6 for clinical reasons they should be admitted into a single room, preferentially room 7.

Non-haematological patients with influenza-like illness should not be admitted to the B6.

About this Canterbury DHB document (206721):

Document Owner:

Andrew Butler (see Who's Who)

Last Reviewed:

May 2021

Next Review:

May 2023


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 206721